Follicular lymphoma (FL) is a rare, slow-growing cancer that affects certain blood cells. People experiencing this form of non-Hodgkin lymphoma face multiple relapses over the course of their disease, which can run for years and sometimes decades. There is no cure. For a small number of patients, the disease progresses much faster, and they face five-year survival rates as low as 50 percent.
MI Philanthropy, in partnership with the Follicular Lymphoma Foundation (FLF), conducted an in-depth analysis of the FL landscape. This report identifies current and emerging therapeutic innovations in the FL field, and highlights efforts of the FLF to drive research into better treatments and find the fastest pathway to a cure. Importantly, this analysis demonstrates that although drug development for FL has been burgeoning in the past five years, there are key areas that should be addressed to accelerate the path to a cure.
Related Content
-
Citi's Christopher Hite Joins FasterCures Advisory Board
Hite’s decades of healthcare finance experience will enhance center’s approach to biomedical innovation WASHINGTON, August 13, 2019 – FasterCures, a center of the Milken Institute, today announced the appointment of Christopher Hite, Vice...Read Article -
Milken Institute Global Conference Scheduled for October 17-20, 2021
Los Angeles – April 15, 2021 – The Milken Institute Global Conference, an annual convening of global leaders in government, finance, health, academia, and philanthropy, will take place this fall from October 17-20, 2021 at The Beverly...Milken Institute Global Conference Scheduled for October 17-20, 2021
-
2023-2026 National Health Security Strategy (NHSS)
Submitted electronically Ms. Dawn O’Connell Assistant Secretary for Preparedness and Response HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) 200 Independence Ave. Washington, DC 20201 Re: 2023-2026 National...Read LetterImageEsther Krofah
Executive Vice President, Milken Institute HealthEsther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives. -
Patient-Reported Outcomes: Design with the End in Mind
“What outcomes matter to patients?” This question is asked at nearly every meeting in biomedical R&D and health care. As FasterCures has documented over the years, there is a big change afoot to place patients in the center of medical...Read Report -
Obesity in the Workplace: What Employers Can Do Differently
The Milken Institute Center for Public Health (the Center) focuses on chronic disease research, policy evaluation, and thought leadership by convening experts and stakeholders. As part of this work, the Center aims to change the public’s...Read Report -
America's Obesity Crisis: The Health and Economic Costs of Excess Weight
This study calculates the prevalence and economic effects of diseases related to obesity and overweight in the United States. These costs are paid by individuals and their households, employers, government, and society. The prevalence of...Read Report11 11Hugh Waters and Marlon Graf -
COVID-19 Silver Linings for Biomedical Innovation: Implementation Roadmap
While the response to the COVID-19 pandemic has exposed many of the fault lines in the biomedical innovation ecosystem that have slowed progress for decades, we have also shown ourselves capable of innovating in ways we perhaps did not...Read Report -
Request for Proposals: Misophonia
The Misophonia Research Fund is pleased to release the 2023 Request for Proposals. The General Grant Program RFP is soliciting research proposals that aim to characterize misophonia, develop objective methods to assess misophonia, or...Read Report -
The Impact of Insight: Patient Preferences in Novel Screening Technologies for Cancer
Patient preferences and insights are increasingly considered throughout the medical product life cycle in addition to clinical outcomes. We know that incorporating patient preferences in the product life cycle can create meaningful results...Patient preferences and insights are increasingly considered throughout the medical product life cycle in addition to clinical outcomes. We know that incorporating patient preferences in the product...
11Katie O'Connor and Hadly Clark -
Coalition-Building Between the US and China on Women’s Cancer Detection, Treatment, and Care
Cancer is one of the leading causes of death in the US and China. Of the top 10 (by incidence) cancers in China, four are women’s cancers, including breast and cervical cancers. Despite successes in cancer control and prevention in both...Read Report -
What Kills Americans: Growth of Metabolic Contributors
The most common way to understand the impact of a disease is to track its rates of prevalence and mortality because these metrics are derived from easily collected data. However, prevalence and mortality rates fail to capture whether a...View Research -
The Reinvention of Prevention: How to Fund and Finance a Pivot to a Prevention-First Healthcare System
As part of the debut of the Milken Institute’s Project Prevent initiative in 2024, the Institute conducted a series of interviews with 35 key stakeholders and experts in health, finance, philanthropy, pensions, and public policy to explore...Read Report